Can Stored Blood Show More Free THCCOOH Without New Cannabis Exposure?

Yes. In a controlled storage study, free THCCOOH increased in some blood samples while its glucuronide decreased. Because these were stored specimens, that change did not represent new cannabis exposure. It demonstrates why the chemical form and storage history belong in an interpretation.

The samples came from actual cannabis exposure

The investigators studied blood and plasma collected from ten participants after controlled cannabis smoking. They prepared lower- and higher-concentration pools from each participant and compared different storage times and temperatures with early measurements.

These were authentic human specimens, not only blank blood fortified with standards. That distinction matters because binding and other matrix characteristics in authentic samples can differ from those in spiked validation materials.

Free metabolite and conjugate did not move together

After one week at room temperature, free THCCOOH increased in both lower- and higher-concentration blood pools, while THCCOOH-glucuronide decreased. At refrigerated temperature, increases in free THCCOOH also appeared in the lower-concentration pools after longer storage. The same pattern did not apply uniformly to every pool or condition.

The authors examined the molar sum of free metabolite and conjugate as well as individual concentrations. This helps distinguish conversion between chemical forms from a simple claim that all cannabinoid material either remained unchanged or disappeared.

Why a later result needs its own context

A repeat test may legitimately differ because the stored material changed. That possibility does not prove that every discrepancy is caused by glucuronide breakdown, and the study cannot provide a universal correction factor for a different tube, preservative, temperature or storage interval.

Review the collection and separation records, storage temperature, elapsed time, analytes reported and whether hydrolysis was performed. Whole blood and plasma should also remain separate: the paper documented matrix-specific stability rather than one interchangeable cannabinoid shelf life.

THCCOOH is an exposure-related metabolite. A storage-related increase in its free form supplies neither a new-use event nor a measure of contemporaneous impairment. Our article on THC concentration and impairment explains that further distinction. The practical lesson is to compare like analytes under documented conditions before attributing a changed number to changed human behavior.

Primary research

Karl B. Scheidweiler and colleagues. Clinical chemistry (2013). In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us